8 -8 (46) 2022 — Asatova M.M., Azizova G.D. — FEATURES OF CLINICAL AND HORMONAL DISORDERS IN WOMEN WITH VARIOUSFORMSOFHYPERANDROGENISM

FEATURES OF CLINICAL AND HORMONAL DISORDERS IN WOMEN WITH VARIOUSFORMSOFHYPERANDROGENISM

Asatova M.M., Republican Specialized Scientific and Practical Medical Center for Obstetrics and Gynecology

Azizova G.D. Republican Specialized Scientific and Practical Medical Center for Obstetrics and Gynecology

Resume

 As a result of a thorough study of anamnestic information: – family history; – age of menarche; – generative history; – the nature of menstrual dysfunction; – the time of manifestations of hirsutism; – the nature of the spread of hirsutism; – height of patients; – according to the ultrasound data of the studied women, we were able to assume the etiology of hyperandrogenism (HA) and divide 256 women with clinical manifestations of HA and impaired reproductive function into two groups: HA of ovarian genesis and HA of adrenal genesis and study the hormonal status depending on the genesis of HA. The LH indicators ​​in all patients with HA were significantly higher than in the control group, while the FSH indicators ​​in both groups were normal, however, the ratio of the LH/FSH coefficient was 3.04±0.58 in the first group, in the second group it was 2, 19 ± 0.89 (p=0.07), while the indicators of biochemical markers of hyperandrogenism of free testosterone, DHEA-S and 17-OHP were higher in women with adrenal HA than in the group of patients with ovarian HA compared with the control group (p>0.05).

Key words: infertility, hyperandrogenism, menstrual dysfunction, miscarriage, reproductive age.

First page

44

Last page

50

For citation: Asatova M.M., Azizova G.D. FEATURES OF CLINICAL AND HORMONAL DISORDERS IN WOMEN WITH VARIOUSFORMSOFHYPERANDROGENISM //New Day in Medicine 8(46)2022 44-50 https://clck.ru/sQ5Uq

LIST OF REFERENCES:

1. Arlt  W, Willis D.S, Wild S.H, Krone N, Doherty E.J, Hahner S, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. // J ClinEndocrinolMetab. (2010) 95:5110–21. doi: 10.1210/jc.2010-0917
2. Azizova G. D., AsatovaM.M. ,Nadyrkhanova N. S. , Dauletova M. J. Polycystic Ovary Syndrome As A Predictor Of Metabolic Syndrome In Women Of Reproductive Age Nat. Volatiles &Essent. Oils, 2021; 8(4): 15615-15618.
3. Azziz R., Carmina E., Chen Z., Dunaif A., et al. Polycystic ovary syndrome // Nat Rev Dis Primers. — 2016; 2: 16057.
4. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. FertilSteril. 2012; 97(Suppl 1):28.e25–38.e25. [PubMed: 22153789]
5. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary
   syndrome (PCOS): the hypothesis of PCOS as functional ovarian
   hyperandrogenism revisited. // Endocr Rev. 2016;37(5):467-520.
6. Teede H. J., Misso M. L., Costello M. F., Dokras A., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome // FertilSteril. — 2018; 89 (3): 251-268.
7. Voutilainen R, Jääskeläinen J. Premature adrenarche: etiology, clinical findings, and consequences. // J Steroid BiochemMol Biol. (2015) 145:226–36. doi: 10.1016/j.jsbmb.2014.06.004
8. Witchel SF, Azziz R. Nonclassic congenital adrenal hyperplasia. // Int J PediatrEndocrinol. (2010) 2010:625105. doi: 10.1186/1687-9856-2010-625105
9. Witchel SF. Non-classic congenital adrenal hyperplasia. Steroids. (2013) 78:747–50. doi:10.1016/j.steroids.2013.04.010.
10. Zawadski J.K. Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif, A.; Givens, JR.; Haseltine, F., editors. Polycystic Ovary Syndrome. Vol. 1992. Boston, MA: Black-well Scientific; p. 377-384.
11. Popova P. V., Gorelova I. V., Grineva E. V. Polycystic ovary syndrome and cardiovascular risk // Arterial hypertension. – 2018. – T. 24. – No. 6. – S. 654-665.